Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Lifevantage Corporation Common Stock (Delaware)

LFVN

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product. Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.

Last trade $4.88
Day change +$0.11 (+2.31%)
Day range $4.76 – $5.00
Volume 68,646
Market cap $60M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$60.49M
Price / earnings
17.22×
Price / book
1.82×
Price / sales
0.34×
EV / sales
0.27×
EV / EBITDA
6.61×

Profitability

Earnings per share
$0.28
Return on assets
5.94%
Return on equity
10.57%
Dividend yield
3.97%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.91×
Quick ratio
1.12×
Cash ratio
0.76×

Cash flow

Price / cash flow
10.46×
Price / free cash flow
30.46×
Free cash flow
$1.99M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for LFVN, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q4 FY2026 Jun 30, 2026Q2 FY2026 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q1 FY2026 Sep 30, 2025Q4 FY2025 Jun 30, 2025Q2 FY2025 Dec 31, 2024Q1 FY2025 Sep 30, 2024
Revenue$37.12M$42.38M$48.93M$47.56M$47.56M$55.11M$67.76M$47.21M
Cost of revenue$9.15M$9.33M$12.72M$9.75M$9.75M$11.07M$13.2M$9.49M
Gross profit$27.97M$33.04M$36.21M$37.82M$37.82M$44.05M$54.57M$37.72M
Selling, general and administrative$12.73M$13.87M$15.83M$14.85M$14.85M$18.68M$18.61M$14.85M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$28.11M$31.38M$35.72M$35.55M$35.55M$41.9M$51.14M$35.15M
Operating income-$136K$1.67M$487K$2.27M$2.27M$2.15M$3.43M$2.57M
Interest expense$45K$164K$0$87K$0$431K$0$0
Income before taxes-$184K$1.7M$473K$2.24M$2.24M$2.4M$3.09M$2.58M
Income taxes$12K$417K$197K$86K$86K$437K$539K$752K
Net income-$196K$1.28M$276K$2.16M$2.16M$1.96M$2.55M$1.83M
Net income attributable to common shareholders-$196K$1.28M$276K$2.16M$2.16M$1.96M$2.55M$1.83M
EBITDA$594K$2.36M$1.24M$2.88M$2.88M$2.9M$4.23M$3.37M
Basic earnings per share-$0.02$0.10$0.02$0.17$0.17$0.16$0.21$0.15
Diluted earnings per share-$0.02$0.10$0.02$0.17$0.17$0.15$0.19$0.14

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Lifevantage (LFVN) Surpasses Q1 Earnings Estimates

Lifevantage reported Q3 2026 earnings of $0.05 per share, beating consensus estimates of $0.03 by 66.67%, but revenues of $37.12 million missed expectations by 3.84%. The company's year-over-year performance declined significantly with EPS down from $0.18 and revenues down from $47.56 million. The stock has underperformed the S&P 500 by 23.1% year-to-date and carries a Zacks Rank #3 (Hold) rating.

Zacks Investment Research

McKesson (MCK) Beats Q2 Earnings and Revenue Estimates

McKesson reported quarterly earnings of $11.68 per share, beating consensus estimates of $10.69, representing a 9.26% earnings surprise. The company posted revenues of $110.96 billion, surpassing estimates by 0.77%. McKesson has outperformed the S&P 500 by 11.3% year-to-date. However, the stock received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Medical-Dental Supplies industry ranks in the top 39% of Zacks industries.

Zacks Investment Research

Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Surpass Estimates

Pro-Dex (PDEX) reported Q3 earnings of $0.92 per share, beating consensus estimates by 37.31%, with revenues of $20.56 million. The company has outperformed the S&P 500 by 64.2% year-to-date and received a Zacks Rank #1 (Strong Buy) rating. However, the Medical-Dental Supplies industry ranks in the bottom 32% of Zacks industries, which could limit future performance.

Zacks Investment Research

New Strong Sell Stocks for October 19th

Zacks has added three stocks to its Strong Sell list today: Camping World (CWH), LifeVantage (LFVN), and Centerra Gold (CGAU). All three companies have experienced significant downward revisions to their current year earnings estimates over the last 60 days, with CWH and LFVN seeing particularly steep declines of 44.4% and 40% respectively.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily
Declared upcoming dividend $0.05 per share
Declared
Nov 5, 2026
Ex-dividend
Dec 1, 2026
Pay date
Dec 15, 2026
Ex-dividendAmount / sharePay dateType
Sep 1, 2026$0.05Sep 15, 2026recurring
Jun 1, 2026$0.05Jun 15, 2026recurring
Mar 2, 2026$0.045Mar 16, 2026recurring
Dec 1, 2025$0.045Dec 15, 2025recurring
Sep 8, 2025$0.045Sep 16, 2025recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 19, 20151-for-7reverse split